# IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact

Study · id `cardio:ct-nct04221815` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04221815](<https://clinicaltrials.gov/study/NCT04221815>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04221815

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 3100 participants.

## Technical summary

Registry record NCT04221815. Randomized; single masking; primary purpose treatment. Start 2020-10-14 (actual); primary completion 2026-09 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 3100 participants (planned count; ClinicalTrials.gov record NCT04221815, source copy `cardio:ctgov-nct04221815-2025-09-12`, retrieved 2026-10-31)
- Started: 2020-10-14 (actual) (ClinicalTrials.gov record NCT04221815, source copy `cardio:ctgov-nct04221815-2025-09-12`, retrieved 2026-10-31)
- Primary completion: 2026-09 (anticipated) (ClinicalTrials.gov record NCT04221815, source copy `cardio:ctgov-nct04221815-2025-09-12`, retrieved 2026-10-31)
- Completion: 2027-09 (anticipated) (ClinicalTrials.gov record NCT04221815, source copy `cardio:ctgov-nct04221815-2025-09-12`, retrieved 2026-10-31)
- Countries: United States; Cyprus; Germany; Greece; Israel; Italy; Sweden; United Kingdom (ClinicalTrials.gov record NCT04221815, source copy `cardio:ctgov-nct04221815-2025-09-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04221815-2025-09-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: IMPact on Revascularization Outcomes of IVUS Guided Treatment of Complex Lesions and Economic Impact
- Acronym: IMPROVE
- Condition: Atherosclerosis
- Intervention (Device): Eagle Eye Platinum digital IVUS catheter with optional SyncVision
- Intervention (Device): Resolute Onyx Drug Eluting Stent
- Intervention (Device): Onyx Frontier Drug Eluting Stent
- Intervention (Device): Onyx TruStar Drug Eluting Stent
- Intervention (Device): Onyx TruCor Drug Eluting Stent
- Lead sponsor: Medstar Health Research Institute
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Medstar Health Research Institute (`cardio:org-medstar-health-research-institute`)

## Provenance

Content hash: 8bf6593c6fdad0f3130a7b790bb15154865df9a6c9521e0325ddd95d207f3789
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
